<DOC>
	<DOCNO>NCT01974752</DOCNO>
	<brief_summary>Selumetinib therapy patient metastatic uveal melanoma .</brief_summary>
	<brief_title>Selumetinib ( AZD6244 : ARRY-142886 ) ( Hyd-Sulfate ) Metastatic Uveal Melanoma ( SUMIT )</brief_title>
	<detailed_description>A randomised double-blind study assess efficacy selumetinib ( AZD6244 , Hyd-Sulfate ) combination Dacarbazine compare placebo combination Dacarbazine first systemic therapy patient metastatic uveal melanoma ( SUMIT )</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<criteria>Clinical diagnosis metastatic uveal melanoma ; Written consent female male patient age 18 year . Histological cytological confirmation melanoma suitable treatment dacarbazine chemotherapy . At least one lesion accurately measure baseline &gt; /=10mm long diameter . ( except lymph node must short axis ≥15 mm ) CT MRI suitable accurate repeat measurement ECOG performance status 01 life expectancy &gt; 12 week Normal organ marrow function Evidence postmenopausal status , negative urinary serum pregnancy test female premenopausal patient Patients able swallow selumetinib/placebo capsule Involvement plan and/or conduct study ( applies AstraZeneca staff and/or staff study site ) Previous randomisation present study Patients previously treat systemic anticancer therapy . Patients prior intrahepatic nonsystemic therapy . Having receive follow within specify timeframe : Any prior systemic anticancer therapy treatment current diagnosis , An investigational drug within 30 day start treatment within five halflives compound ( whichever appropriate discretion Investigator ) , recover side effect investigational drug Any nonsystemic anticancer therapy clear body time start study treatment Radiation therapy within 4 week prior start study treatment , limited field radiation palliation within 7 day first dose study treatment Major surgery within 4 week prior entry study ( exclude placement vascular access ) would prevent administration study treatment , Any prior investigational therapy comprise inhibitor RAS , RAF MEK time , Previous treatment dacarbazine . Any unresolved toxicity &gt; CTCAE grade 2 previous anticancer therapy , exclude alopecia History allergic reaction attribute compound similar chemical biologic composition selumetinib dacarbazine Symptomatic brain metastasis spinal cord compression ( patient must treat stable steroid anticonvulsant least 1 month prior entry study ) Cardiac condition follow : Uncontrolled hypertension ( BP ≥150/95 mmHg despite medical therapy ) Acute coronary syndrome within 6 month prior start treatment Uncontrolled Angina Canadian Cardiovascular Society grade IIIV despite medical therapy Symptomatic heart failure ( New York Heart Association [ NYHA ] Class IIIV , Prior current cardiomyopathy Baseline LVEF &lt; 55 % measure echocardiography MUGA . Appropriate correction use MUGA perform Severe valvular heart disease Atrial fibrillation ventricular rate &gt; 100 bpm ECG rest QTcF &gt; 450 m factor increase risk QTc prolongation Any evidence severe uncontrolled systemic disease , active infection , active bleeding diatheses renal transplant , include patient know hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) Refractory nausea vomiting , chronic gastrointestinal disease ( eg inflammatory bowel disease ) , significant bowel resection would preclude adequate absorption History another primary malignancy within 5 year prior start study treatment , except adequately treat basal squamous cell carcinoma skin cancer cervix situ disease study Ophthalmologic condition : Current past history central serous retinopathy Current past history retinal vein occlusion IOP &gt; 21 mmHg uncontrolled glaucoma ( irrespective IOP ) Female patient breastfeed child male female patient reproductive potential employ effective method birth control Clinical judgement Investigator patient participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>uveal melanoma</keyword>
</DOC>